Iovance Biotherapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell IOVA and other ETFs, options, and stocks.About IOVA
Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors.
CEOFrederick G. Vogt
CEOFrederick G. Vogt
Employees557
Employees557
HeadquartersSan Carlos, California
HeadquartersSan Carlos, California
Founded2007
Founded2007
Employees557
Employees557
IOVA Key Statistics
Market cap3.27B
Market cap3.27B
Price-Earnings ratio-6.18
Price-Earnings ratio-6.18
Dividend yield—
Dividend yield—
Average volume4.14M
Average volume4.14M
High today$12.13
High today$12.13
Low today$11.68
Low today$11.68
Open price$11.93
Open price$11.93
Volume2.59M
Volume2.59M
52 Week high$18.33
52 Week high$18.33
52 Week low$3.21
52 Week low$3.21
IOVA News
Yahoo Finance 8h
Iovance Biotherapeutics to Present Clinical and Translational Data at 2024 ASCO Annual Meeting - Yahoo FinanceIovance Biotherapeutics, Inc. Oral Presentation of Updated Results of IOV-COM-202 Cohort 1A of Lifileucel plus Pembrolizumab in Advanced Frontline Melanoma SA...
Analyst ratings
93%
of 14 ratingsBuy
92.9%
Hold
7.1%
Sell
0%